Kilitch Drugs (India) Ltd - Stock Valuation and Financial Performance

BSE: 524500 | NSE: KILITCH | Pharmaceuticals & Drugs | Small Cap

Kilitch Drugs(India) Share Price

389.95 -0.25 -0.06%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Kilitch Drugs(India)

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Kilitch Drugs (India) stock performance -

mw4me loader
P/E Ratio (SA):
32.90
Market Cap:
627 Cr.
52-wk low:
136.6
52-wk high:
469.9

Is Kilitch Drugs (India) Ltd an attractive stock to invest in?

1. Is Kilitch Drugs (India) Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kilitch Drugs (India) Ltd is a below average quality company.

2. Is Kilitch Drugs (India) Ltd undervalued or overvalued?

The key valuation ratios of Kilitch Drugs (India) Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Kilitch Drugs (India) Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Kilitch Drugs (India) Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Kilitch Drugs(India):

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kilitch Drugs (India) Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -1.8%-0.1%-1.9%0.4%4.1%9.2%1.7%3.1%5.3%7.1%-
Value Creation
Index
-1.1-1.0-1.1-1.0-0.7-0.3-0.9-0.8-0.6-0.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 14.9192128.150.596.460.870105118136
Sales YoY Gr.-27.7%10.5%33.9%79.3%91.1%-37%15.2%50.2%12%-
Adj EPS -1.6-0.1-1.70.33.68.51.3368.911.9
YoY Gr.-NANANA1332%136.3%-84.2%123.1%100.7%49%-
BVPS (₹) 89.889.688.188.992.897.797.5104.9112.4122.3135
Adj Net
Profit
-2.2-0.2-2.30.34.9132.14.69.413.919
Cash Flow from Ops. -31.1-7.6180.6-1.37.47.36.15.26.1-
Debt/CF from Ops. 0001.1-0.61.31.72.43.93.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 25.8%18.5%24.7%12%
Adj EPS NA20.1%88.3%49%
BVPS3.5%5.7%7.9%8.8%
Share Price 35.2% 14.6% 68% 177.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
-1.8-0.1-1.90.33.99.21.435.57.59.2
Op. Profit
Mgn %
-25.2-6-150.511.1171.97.611.314.716
Net Profit
Mgn %
-14.4-0.8-10.71.29.813.53.46.68.911.814
Debt to
Equity
000000.10.10.10.10.1-
Working Cap
Days
632725536280193173373364299314152
Cash Conv.
Cycle
117170244163866410759394181

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 9.20%

Sales growth is growing at healthy rate in last 3 years 24.68%

Net Profit is growing at healthy rate in last 3 years 88.25%

Sales growth is good in last 4 quarters at 28.09%

No data to display

Latest Financials - Kilitch Drugs (India) Ltd.

Standalone Consolidated
TTM EPS (₹) 11.9 9.1
TTM Sales (₹ Cr.) 136 155
BVPS (₹.) 135 105.2
Reserves (₹ Cr.) 201 153
P/BV 2.89 3.71
PE 32.90 43.03
From the Market
52 Week Low / High (₹) 136.55 / 469.85
All Time Low / High (₹) 0.75 / 469.85
Market Cap (₹ Cr.) 627
Equity (₹ Cr.) 16.1
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Kilitch Drugs(India):

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Kilitch Drugs(India)

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales1519212850966170105118
Operating Expenses 192125294581606594100
Manufacturing Costs3244345588
Material Costs67911265336396058
Employee Cost 3333456567
Other Costs 78910111813152027
Operating Profit -4-2-4-1616151117
Operating Profit Margin (%) -25.2%-8.6%-16.9%-2.0%11.1%16.2%1.9%7.6%10.6%14.7%
Other Income 6332366455
Interest 0000011111
Depreciation 1221111111
Exceptional Items 0000000000
Profit Before Tax 1-1-20720581419
Tax 0-100151134
Profit After Tax 10-20615461116
PAT Margin (%) 7.9%-1.0%-9.8%-0.1%12.3%15.3%7.3%8.8%10.0%13.3%
Adjusted EPS (₹)0.9-0.1-1.60.04.59.62.94.06.810.1
Dividend Payout Ratio (%)0%0%0%0%11%5%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 119119117118127150150163175191
Share Capital 13131313141515151616
Reserves 106105103104114135135147160175
Minority Interest0000000000
Debt00011913152022
Long Term Debt0000000000
Short Term Debt00011913152022
Trade Payables5246858142829
Others Liabilities 6544862489
Total Liabilities 129126125128144171173195231250

Fixed Assets

Gross Block24232324252627283638
Accumulated Depreciation15131516171820212223
Net Fixed Assets998878871415
CWIP 0000000001
Investments 4072929610110098107117110
Inventories3233356452
Trade Receivables9131615212317234153
Cash Equivalents 445324436218
Others Assets24253493242495051
Total Assets 129126125128144171173195231250

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity -31-8181-177656
PBT 1-1-20720581419
Adjustment -4211-1-3-4002
Changes in Working Capital -28-9200-7-590-6-11
Tax Paid 00000-4-2-1-3-4
Cash Flow From Investing Activity 72-31-20-1-2-22-10-5-166
Capex 000-1-1-2-10-8-4
Net Investments 7211-200-2200-77
Others 0-42-101-22-9-5-13
Cash Flow From Financing Activity 00006151283
Net Proceeds from Shares 0000300000
Net Proceeds from Borrowing 0000000000
Interest Paid 00000000-1-1
Dividend Paid 00000-1-2000
Others 00003153284
Net Cash Flow 41-39-2020-13-315
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)1.06-0.16-1.75-0.035.0610.652.973.936.238.59
ROCE (%)0.98-0.66-2.04-0.266.0113.793.794.917.839.9
Asset Turnover Ratio0.110.150.170.220.370.610.350.380.490.49
PAT to CFO Conversion(x)-31INFN/A-INF-0.170.471.7510.450.38
Working Capital Days
Receivable Days25820425220112783121104112146
Inventory Days51484334191431241511
Payable Days565183125150944568100125177

Kilitch Drugs (India) Ltd Stock News

Kilitch Drugs (India) Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Kilitch Drugs(India) on 28-Mar-2024 16:01 is ₹389.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Kilitch Drugs(India) stood at ₹627.0.
The latest P/E ratio of Kilitch Drugs(India) as of 28-Mar-2024 16:01 is 32.90.
The latest P/B ratio of Kilitch Drugs(India) as of 28-Mar-2024 16:01 is 2.89.
The 52-week high of Kilitch Drugs(India) is ₹469.9 and the 52-week low is ₹136.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kilitch Drugs(India) is ₹135.8 ( Cr.) .

About Kilitch Drugs (India) Ltd

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.

Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.

Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.

In 2010 the company listed its Equity Shares at NSE.

DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam

Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials

Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.

Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.